# Inside the KLOW Stack: The Four Peptides | KLOW Peptide Research Dossier > Inside the KLOW stack — KPV, GHK-Cu, BPC-157, and TB-500 examined as four separate peptide arms with their own mechanisms, studies, and evidence limits. KLOW peptide research. KPV, GHK-Cu, BPC-157, and TB-500 — each examined on its own evidence, with the combination gap stated plainly and the KLOW-vs-GLOW distinction set out at the structural level. ## In plain English The KLOW stack is four separate peptides in one vial. This page opens each arm of that vial and explains what it is, what the research has measured, and what remains uncharacterized. 'Stack' is a research-community word for a combination of compounds; the word does not imply the combination has been tested as one. KPV is the anti-inflammatory arm — the reason KLOW differs from GLOW. GHK-Cu is the copper-bearing matrix peptide that makes up most of the vial by weight. BPC-157 is the tissue-repair peptide with the largest animal-model dataset. TB-500 is the shortest fragment of the four components and the one whose headline data come from a different, longer protein. The klow stack itself — meaning this exact four-peptide combination — has never been tested in a controlled study. Everything on this page is drawn from the single-component literatures. That boundary is the most important thing to understand about the KLOW stack before reading anything else. ## KPV: the anti-inflammatory lead arm KPV (Lys-Pro-Val, CAS 67727-97-3, 342.44 Da) is the C-terminal tripeptide of alpha-MSH — the 13-residue anti-inflammatory signaling peptide secreted by the pituitary. Its role in the KLOW stack is as the feature's lead constituent: it is what the GLOW blend lacks, and it is the mechanistic through-line of this dossier. The definitive mechanistic study is Dalmasso et al. (2008, Gastroenterology): KPV is a substrate of the PepT1 di/tripeptide transporter (SLC15A1, Km ~160 microM), which is upregulated in inflamed intestinal epithelium, meaning KPV is actively delivered to the cells that need it most in an inflammatory context. At nanomolar concentrations — far below what would typically be considered a pharmacological dose — KPV blocked NF-kappaB nuclear import in Caco2-BBE and HT29-Cl.19A human intestinal epithelial cells, suppressed MAPK (ERK and p38) activation, and reduced output of TNF-alpha, IL-6, IL-1beta, and IL-8 [1]. Oral KPV at 100 microM in drinking water reduced DSS-induced and TNBS-induced colitis severity in C57BL/6 mice. Kannengiesser et al. (2008, Inflamm Bowel Dis) confirmed anti-colitis activity in DSS and CD45RB-hi adoptive-transfer models, with the important mechanistic clarification that KPV's effect was retained in MC1R-deficient mice — ruling out melanocortin-1 receptor dependence [9]. Getting et al. (2003, J Pharmacol Exp Ther) characterized the distinction from core alpha-MSH peptides: KPV reduced leukocyte accumulation but did not suppress macrophage cytokine release, pointing to an IL-1beta-directed mechanism [8]. ## GHK-Cu: the mass-dominant matrix arm GHK-Cu (Gly-His-Lys copper(II), CAS 89030-95-5, 402.92 Da) is the dominant constituent of the KLOW vial — 50 of 80 mg, approximately 62.5% by mass. It was first isolated from human plasma by Loren Pickart in 1973 and is one of the most-studied peptides in cosmetic and wound-healing research. The mass-dominance of GHK-Cu is a feature of the blend's composition, not a pharmacological signal. The 50 mg share is the supplier convention; it does not follow from a dose-optimization study. What GHK-Cu's individual research record actually contains: stimulation of collagen, dermatan sulfate, chondroitin sulfate, and decorin synthesis; a decline in plasma GHK from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60; and a topical clinical comparison in which GHK-Cu increased collagen production in 70% of women versus 50% for vitamin C [4]. At the gene-expression level, the 2018 Pickart and Margolina analysis estimated that GHK modulates approximately 31% of human protein-coding genes at a ≥50% change threshold, with particular effects on extracellular-matrix remodeling, antioxidant programs, DNA repair, and the ubiquitin-proteasome system [5]. The 2025 Mao et al. study in Frontiers in Pharmacology adds a SIRT1/STAT3 pathway signal in colitis — the same inflammatory milieu that KPV targets via NF-kappaB/MAPK — suggesting the two arms may operate on partially overlapping territory from different molecular entry points [14]. ## BPC-157: the angiogenic tissue-repair arm BPC-157 (GEPPPGKPADDAGLV, CAS 137525-51-0, 1419.53 Da) is a synthetic 15-amino-acid peptide derived from a partial sequence of a gastric-juice protein, originally developed under the name PL 14736 for inflammatory bowel disease. Its preclinical tissue-repair record is the most extensive of any KLOW constituent. Staresinic et al. (2003) demonstrated that BPC-157 at 10 microg, 10 ng, and 10 pg per rat accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, and stimulated tendocyte outgrowth in vitro [2]. The dose-response breadth — from micrograms to picograms — is notable and has been a consistent feature of BPC-157 preclinical literature. BPC-157 activates the VEGFR2/PI3K/Akt/eNOS angiogenic axis and upregulates the growth-hormone receptor in tendon fibroblasts. Human data remain very limited: the 2025 IV safety pilot by Lee and Burgess reported no adverse events in two adults at 10 and 20 mg [6]. A 2026 Sports Medicine review named BPC-157 among unapproved musculoskeletal peptides with favorable animal-model data but scarce human safety evidence [7]. ## TB-500: the cytoskeletal arm and the fragment distinction TB-500 (Ac-LKKTETQ, 889.02 Da) is the KLOW constituent with the largest gap between its published headline finding and what that finding actually establishes for the specific molecule sold under that name. The headline finding — +42% re-epithelialization at four days and +61% at seven days in a rat full-thickness wound model (Malinda et al., 1999, J Invest Dermatol) [3] — is a thymosin beta-4 finding. The study used full-length native thymosin beta-4, a 43-amino-acid protein; TB-500 is a synthetic heptapeptide (seven amino acids) corresponding to thymosin beta-4's LKKTET actin-binding motif. Most of the published efficacy literature — including the wound-healing, cardiac repair, and epicardial progenitor findings — is for the native protein, not the fragment. What the fragment mechanism establishes is more limited: the LKKTET motif sequesters G-actin, holding monomeric actin in reserve rather than allowing polymerization, a step mechanistically linked to cell migration. The 2026 Sports Medicine systematic review confirmed that TB-500/thymosin beta-4 belongs to the category of unapproved musculoskeletal peptides with animal-model promise but thin human safety data [7]. The WADA prohibition applies: thymosin beta-4 is on the WADA Prohibited List (S2) at all times in and out of competition. Because TB-500 is marketed as a fragment of thymosin beta-4, it implicates this prohibition. ## KLOW vs GLOW The GLOW blend contains GHK-Cu, BPC-157, and TB-500 in a single research vial. KLOW adds KPV as a fourth component, shifting the blend's profile from a matrix/angiogenic/cytoskeletal combination to one that also covers the NF-kappaB/MAPK inflammatory-signaling axis via the gut epithelium. The addition is meaningful at the molecular level: PepT1-mediated KPV uptake into inflamed intestinal epithelium is a mechanism that none of the GLOW components replicates. NF-kappaB inhibition at nanomolar concentrations is a mechanistic signal that the other three components do not share. Whether the addition produces additive or synergistic effects in vivo, in the combination — no study has measured this. The 'KLOW vs GLOW' comparison is a compositional comparison, not an outcome comparison. No controlled head-to-head study has tested the two blends against each other. --- A midnight-editorial dossier on four separate peptide literatures — each constituent kept to its own studies, the blend's column left blank because no controlled trial has filled it, and nothing here dispensed, dosed, or sold.